Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)-Reference-Cited by-同舟云学术

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)

Published:2015-03-23 Issue:7 Volume:62 Page:1214-1221
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Houghton Peter J.¹,Kurmasheva Raushan T.¹,Kolb E. Anders²,Gorlick Richard³,Maris John M.⁴⁵,Wu Jianrong⁶,Tong Zeen⁷,Arnold Michael A.⁸⁹,Chatterjee Moumita¹⁰,Williams Terence M.¹⁰,Smith Malcolm A.¹¹

Affiliation:

1. Nationwide Children's Hospital; Columbus Ohio

2. A.I. duPont Hospital for Children; Wilmington Delaware

3. The Children's Hospital at Montefiore; Bronx New York

4. Children's Hospital of Philadelphia; University of Pennsylvania School of Medicine; Philadelphia Pennsylvania

5. Abramson Family Cancer Research Institute; Philadelphia Pennsylvania

6. St. Jude Children's Research Hospital; Memphis Tennessee

7. Celgene Corporation; Los Angeles California

8. Department of Pathology and Laboratory Medicine; Nationwide Children's Hospital; Columbus Ohio

9. Department of Pathology; The Ohio State University College of Medicine; Columbus Ohio

10. James Cancer Hospital; Columbus Ohio

11. Cancer Therapy Evaluation Program; NCI; Bethesda Maryland

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference26 articles.

1. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients;Desai;Transl Oncol,2009

2. Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel;de Leon;Gynecol Oncol Case Rep,2013

3. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer;Miele;Int J Nanomed,2009

4. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: A pediatric oncology group study;Hayashi;J Pediatr Hematol Oncol,2003

5. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: A pediatric oncology phase II study;Hurwitz;J Pediatr Hematol Oncol,2001

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality-by-Design (QbD) Assisted Synthesis of Nanoparticle for Efficient Loading, Stabilization, and Intracellular Delivery of Bioactive for the Treatment of Arthritis;Indian Journal of Microbiology;2024-07-29

2. Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future;Medicinal Research Reviews;2024-06-17

3. Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma;Frontiers in Molecular Biosciences;2024-03-26

4. Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma;Biochemical Pharmacology;2023-02

5. Nanoformulations applied to the delivery of alkaloids;Phytochemical Nanodelivery Systems as Potential Biopharmaceuticals;2023